Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs is dedicated to genotyping services for our global clients. With advanced technology platforms and extensive expertise, we are ready to provide you with high-quality KIR typing services.
As an important lymphocyte population in the innate immune system, natural killer (NK) cells are critical in lysing the infected cells or cancer cells without adaptive immune response mediated by antigen stimulation. Killer-cell immunoglobulin-like receptors (KIRs) are type I transmembrane glycoproteins expressed on NK cells, and they can interact with major histocompatibility (MHC) class I molecules to mediate the inhibitory or activated NK cell activities. For normal healthy tissues, negative regulation of NK cell happens via the recognition of MHC molecules with inhibitory KIRs. For infected cells or transformed cells, NK cells can lyse the target cells through activated KIRs. KIR molecules are highly polymorphic, and the sequences are different between individuals. KIR family consists of 15 gene loci, including KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3, and two pseudogenes, KIR2DP1 and KIR3DP1 (see Fig.1).
Fig.1 KIR proteins. (Source from IPD-KIR)
To investigate the polymorphism of KIRs, Creative Biolabs offers a series of KIR typing services to our clients, including KIR typing at the DNA and mRNA level, as well as KIR phenotyping by FACS.
Fig.2 Pipeline for analyzing sequence data from highly polymorphic KIRs. (Norman, 2016)
With novel technology platform and professional senior scientists, Creative Biolabs provides a full spectrum of KIR typing services covering all KIR genes and alleles. We are committed to offering customized solutions to fit our clients’ specific requirements. Please feel free to contact us for more details.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE